Basic Information
| LncRNA/CircRNA Name | GTSE1-AS1 |
| Synonyms | NA |
| Region | GRCh38_22:46295143-46296660 |
| Ensemble | ENSG00000277232 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | peptide | Recurrence |
Cancer&Entry Information
| Cancer Name | high grade ovarian serous cancer |
| ICD-0-3 | C56 |
| Methods | Microarray, qPCR etc. |
| Sample | high-grade ovarian serous cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | The results demonstrated that FAS-AS1, AK130076, RP11-199F11.2 and AC093818.1 were upregulated and GTSE1-AS1 was downregulated in high-grade ovarian serous cancer tissues compared with healthy fallopian tube tissues. The associations between the expression of the 5 lncRNAs and clinicopathological parameters in patients with high-grade ovarian serous cancer patients are presented in Table VII. The microarray results of the selected lncRNAs are presented in Table VIII. These lncRNAs were significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastases in ovarian cancer. |
| Pubmed ID | 29577163 |
| Year | 2018 |
| Title | Gene microarray analysis of lncRNA and mRNA expression profiles in patients with high-grade ovarian serous cancer. |
External Links
| Links for GTSE1-AS1 | GenBank HGNC NONCODE |
| Links for high grade ovarian serous cancer | OMIM COSMIC |